Limits...
The catalase C-262T gene polymorphism and cancer risk: a systematic review and meta-analysis.

Shen Y, Li D, Tian P, Shen K, Zhu J, Feng M, Wan C, Yang T, Chen L, Wen F - Medicine (Baltimore) (2015)

Bottom Line: Many studies suggest that catalase C-262T gene polymorphism is associated with cancer risk, but with inconsistent results.Subgroup analyses stratified by cancer types suggested the catalase C-262T polymorphism was significantly associated with an increased prostate cancer risk (TT vs CT + CC: OR = 1.61, 95% CI = 1.17-2.22, P = 0.004); for subgroup analyses stratified by ethnicity, no associations between this polymorphism and Asians or whites were identified (CT + TT vs CC: OR = 1.11, 95% CI = 0.98-1.26, P = 0.09 for whites; OR = 1.19, 95% CI = 0.78-1.80, P = 0.42 for Asians).Further studies should be performed to confirm these findings.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China (YS, DL, PT, JZ, MF, CW, TY, LC); and Radiation Physics Center, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, China (KS).

ABSTRACT
Many studies suggest that catalase C-262T gene polymorphism is associated with cancer risk, but with inconsistent results. This study aimed to summarize the overall association between catalase C-262T polymorphism and cancer risk. Literature search was performed in PubMed, Embase, and other databases, studies regarding the association between catalase C-262T polymorphism and cancer risk were identified, and data were retrieved and analyzed by using Review Manager 5.0.24 and STATA 12.0. A total of 18 publications with 22 case-control studies, including 9777 cancer patients and 12,223 controls, met the inclusion criteria. Meta-analysis results showed significant association between catalase C-262 T polymorphism and cancer risk (TT vs CT + CC: odds ratio [OR] = 1.17, 95% confidence interval [CI] = 1.03-1.31, P = 0.01). Subgroup analyses stratified by cancer types suggested the catalase C-262T polymorphism was significantly associated with an increased prostate cancer risk (TT vs CT + CC: OR = 1.61, 95% CI = 1.17-2.22, P = 0.004); for subgroup analyses stratified by ethnicity, no associations between this polymorphism and Asians or whites were identified (CT + TT vs CC: OR = 1.11, 95% CI = 0.98-1.26, P = 0.09 for whites; OR = 1.19, 95% CI = 0.78-1.80, P = 0.42 for Asians). In summary, the catalase C-262T polymorphism may be a risk factor for cancer with cancer type-specific effects. Further studies should be performed to confirm these findings.

Show MeSH

Related in: MedlinePlus

Forest plot for meta-analysis of catalase C-262T polymorphism and cancer risk (TT vs CT + CC). The size of the square is proportional to the weight of each study; horizontal lines represent the 95% confidence interval.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554031&req=5

Figure 2: Forest plot for meta-analysis of catalase C-262T polymorphism and cancer risk (TT vs CT + CC). The size of the square is proportional to the weight of each study; horizontal lines represent the 95% confidence interval.

Mentions: Meta-analysis results showed significant association between CAT C-262T polymorphism and the risk of cancer in additive and recessive genetic models (TT vs CC: OR = 1.19, 95% CI = 1.01–1.40, P = 0.04; TT vs CT + CC: OR = 1.17, 95% CI = 1.03–1.31, P = 0.01, Figure 2), but no evidence of association in other genetic models (T vs C: OR = 1.07, 95% CI = 1.00–1.15, P = 0.06; CT + TT vs CC: OR = 1.05, 95% CI = 0.97–1.13, P = 0.20). These results suggest that individuals who carry the TT homozygote may have an increased risk of cancer compared with the C allele carriers (CC or CT + CC).


The catalase C-262T gene polymorphism and cancer risk: a systematic review and meta-analysis.

Shen Y, Li D, Tian P, Shen K, Zhu J, Feng M, Wan C, Yang T, Chen L, Wen F - Medicine (Baltimore) (2015)

Forest plot for meta-analysis of catalase C-262T polymorphism and cancer risk (TT vs CT + CC). The size of the square is proportional to the weight of each study; horizontal lines represent the 95% confidence interval.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554031&req=5

Figure 2: Forest plot for meta-analysis of catalase C-262T polymorphism and cancer risk (TT vs CT + CC). The size of the square is proportional to the weight of each study; horizontal lines represent the 95% confidence interval.
Mentions: Meta-analysis results showed significant association between CAT C-262T polymorphism and the risk of cancer in additive and recessive genetic models (TT vs CC: OR = 1.19, 95% CI = 1.01–1.40, P = 0.04; TT vs CT + CC: OR = 1.17, 95% CI = 1.03–1.31, P = 0.01, Figure 2), but no evidence of association in other genetic models (T vs C: OR = 1.07, 95% CI = 1.00–1.15, P = 0.06; CT + TT vs CC: OR = 1.05, 95% CI = 0.97–1.13, P = 0.20). These results suggest that individuals who carry the TT homozygote may have an increased risk of cancer compared with the C allele carriers (CC or CT + CC).

Bottom Line: Many studies suggest that catalase C-262T gene polymorphism is associated with cancer risk, but with inconsistent results.Subgroup analyses stratified by cancer types suggested the catalase C-262T polymorphism was significantly associated with an increased prostate cancer risk (TT vs CT + CC: OR = 1.61, 95% CI = 1.17-2.22, P = 0.004); for subgroup analyses stratified by ethnicity, no associations between this polymorphism and Asians or whites were identified (CT + TT vs CC: OR = 1.11, 95% CI = 0.98-1.26, P = 0.09 for whites; OR = 1.19, 95% CI = 0.78-1.80, P = 0.42 for Asians).Further studies should be performed to confirm these findings.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China (YS, DL, PT, JZ, MF, CW, TY, LC); and Radiation Physics Center, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, China (KS).

ABSTRACT
Many studies suggest that catalase C-262T gene polymorphism is associated with cancer risk, but with inconsistent results. This study aimed to summarize the overall association between catalase C-262T polymorphism and cancer risk. Literature search was performed in PubMed, Embase, and other databases, studies regarding the association between catalase C-262T polymorphism and cancer risk were identified, and data were retrieved and analyzed by using Review Manager 5.0.24 and STATA 12.0. A total of 18 publications with 22 case-control studies, including 9777 cancer patients and 12,223 controls, met the inclusion criteria. Meta-analysis results showed significant association between catalase C-262 T polymorphism and cancer risk (TT vs CT + CC: odds ratio [OR] = 1.17, 95% confidence interval [CI] = 1.03-1.31, P = 0.01). Subgroup analyses stratified by cancer types suggested the catalase C-262T polymorphism was significantly associated with an increased prostate cancer risk (TT vs CT + CC: OR = 1.61, 95% CI = 1.17-2.22, P = 0.004); for subgroup analyses stratified by ethnicity, no associations between this polymorphism and Asians or whites were identified (CT + TT vs CC: OR = 1.11, 95% CI = 0.98-1.26, P = 0.09 for whites; OR = 1.19, 95% CI = 0.78-1.80, P = 0.42 for Asians). In summary, the catalase C-262T polymorphism may be a risk factor for cancer with cancer type-specific effects. Further studies should be performed to confirm these findings.

Show MeSH
Related in: MedlinePlus